1025TiP SOLTI-1904: Efficacy of spartalizumab across multiple cancer-types in patients with PD1-high mRNA expressing tumors defined by a single and pre-specified cutoff (ACROPOLI)

Abstract

The immune checkpoint inhibitors against programmed death 1 (PD1) or its ligand (PD-L1) has demonstrated significant efficacy in multiple cancer types. Thus, selecting patients most likely to respond to these therapies is necessary. PD-L1 expression by immunohistochemistry has been proposed as a potential predictive biomarker of response. A statistically significant difference in Overall Response Rate (ORR) between PD-L1 positive and PD-L1 negative tumors has been reported. However, there is not a common reference standard for PD-L1 quantification.